Eva Merry

Eva Merry, as an Equity Partner at Curi Bio, plays a pivotal role in shaping the company's strategic direction and fostering innovation within the rapidly evolving biotechnology sector. Her current responsibilities encompass leading long-term strategic planning initiatives, where she assesses emerging market opportunities and identifies avenues for business expansion. Eva’s expertise in market research and regional market development enables her to pinpoint high-potential areas for growth, ensuring Curi Bio remains at the forefront of biotechnological advancements. She is instrumental in improving the market adaptability of the company’s core technology platforms, leveraging her deep understanding of biotechnology trends and regulatory landscapes to drive product innovation and commercialization.

In her role, Eva also spearheads financing strategies, cultivating and maintaining robust relationships with venture capitalists and strategic investors. Her proficiency in financial planning and analysis (FP&A) ensures that Curi Bio’s growth initiatives are well-funded and aligned with long-term business objectives. She collaborates closely with cross-functional teams—including R&D, business operations, and human resources—to foster a culture of entrepreneurship and innovation, which is critical for navigating the competitive biotech landscape. Through her leadership, Eva has successfully guided the company through complex regional market development projects, expanding Curi Bio’s footprint and strengthening its market presence. Her strategic vision and operational acumen continue to drive sustainable growth, positioning Curi Bio as a leader in tissue engineering and regenerative medicine.